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a b s t r a c t  
Brown adipose tissue (BAT) represents a promising agent to ameliorate obesity and other metabolic disorders. How-
ever, the abundance of BAT decreases with age and BAT paucity is a common feature of obese subjects. As brown 
adipocytes and myoblasts share a common Myf5 lineage origin, elucidating the molecular mechanisms underlying 
the fate choices o f b rown adipocytes  versus myoblasts may lead to novel approaches to expand BAT mass. Here we 
identify MyoD as a key negative regulator of brown adipocyte development. CRISPR/CAS9-mediated deletion of 
MyoD in C2C12 myoblasts facilitates their adipogenic transdifferentiation. MyoD knockout downregulates miR-
133 and upregulates the miR-133 target Igf1r, leading to amplification of PI3K–Akt signaling. Accordingly, inhibition 
of PI3K or Akt abolishes the adipogenic gene expression of MyoD null myoblasts. Strikingly, loss of MyoD converts 
satellite cell-derived primary myoblasts to brown adipocytes through upregulation of Prdm16, a target  of m iR-133  
and key determinant of brown adipocyte fate. Conversely, forced expression of MyoD in brown preadipocytes blocks 
brown adipogenesis and upregulates the expression of myogenic genes. Importantly, miR-133a knockout signifi-
cantly blunts the inhibitory effect of MyoD on brown adipogenesis. Our results establish MyoD as a negative regu-
lator of brown adipocyte development by upregulating miR-133 to suppress Akt signaling and Prdm16. 
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/). 
1. Introduction 
Obesity, caused by an imbalance between energy intake and energy 
expenditure, has become a global health crisis (Hossain et al., 2007). 
Brown adipose tissue (BAT) found prominently in rodents and hibernat-
ing mammals functions to dissipate energy in the form of non-shivering 
thermogenesis mediated by the uncoupling protein Ucp1 (Cannon and 
Nedergaard, 2004; Kopecky et al., 1995). Adult humans also have func-
tional BAT with the capacity to take up and utilize glucose and fatty 
acids for thermogenesis (Cypess et al., 2009; Nedergaard et al., 2007; 
Orava et al., 2011; Ouellet et al., 2012; Pfannenberg et al., 2010; van 
Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). It has been dem-
onstrated that repeated cold treatments activate human BAT in parallel 
to an increase in energy expenditure (van der Lans et al., 2013; 
Yoneshiro et al., 2013). As such, BAT represents a promising target in 
the treatment of obesity and other metabolic disorders. However, BAT 
abundance decreases with age (Cypess et al., 2009; Nedergaard et al., 
2007; Pfannenberg et al., 2010; van Marken Lichtenbelt et al., 2009; 
⁎ Corresponding author at: 174B Smith Hall, 901 West State Street, West Lafayette, IN 
47907, USA. 
E-mail address: skuang@purdue.edu (S. Kuang). 
Virtanen et al., 2009). Understanding the molecular regulation of BAT 
biogenesis is key to the development of novel approaches to expand 
BAT mass. 
Brown adipocytes and myoblasts are derived from a common pool of 
progenitors expressing Myf5 (Seale et al., 2008), the earliest myogenic 
regulatory factor (MRF) detected in developing muscles (Ott et al., 
1991). The fate of brown adipocytes is determined by the expression 
of PR domain containing protein 16 (Prdm16) (Seale et al., 2008). Ec-
topic expression of Prdm16 in myoblasts inhibits myogenesis and the 
expressions of muscle related genes, partly through euchromatic his-
tone-lysine N-methyltransferase 1 and miR-193b-365 (Ohno et al., 
2013; Seale et al., 2008; Sun et al., 2011). MRFs, including Myf5, 
MyoD, Myog and Myf6 (Mrf4) orchestrate the process of myogenesis 
(Olson and Klein, 1994; Pownall et al., 2002). MyoD acts downstream 
of Myf5 to commit somite-derived cells to myoblasts (Rudnicki et al., 
1993), and to initiate the onset of myogenic differentiation (Rawls et 
al., 1998). A lineage-tracing study reveals that the MyoD lineage does 
not give rise to brown adipocytes (Sanchez-Gurmaches and Guertin, 
2014), indicating a role of MyoD in myogenic cell fate switch in the com-
mon Myf5+ progenitors that give rise to both myoblasts and brown 
preadipocytes. However, whether loss of MyoD promotes brown adipo-
cyte cell fate conversion of myoblasts, and whether ectopic expression 
http://dx.doi.org/10.1016/j.ebiom.2017.01.015 
2352-3964/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
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of MyoD in brown preadipocytes inhibits adipogenesis has not been ex-
amined. In this paper, we provide gain- and loss-of-function evidence to 
show that MyoD acts as a key molecular repressor of the brown adipo-
cyte cell fate. 
2. Materials and Methods 
2.1. Animals 
MyoD−/− mice (Rudnicki et al., 1992) were generously provided by 
Dr. Michael Rudnicki (Ottawa Health Research Institute, Ottawa, Ontar-
io, Canada). The miR-133a1/a2 double knockout mice were generously 
provided by Dr. Eric Olson (Liu et al., 2008). The mdx mice 
MyoDiCre/+ (stock#001801, RRID: IMSR_JAX:001801) and mice 
(stock#014140) were from Jackson lab. Mice were housed in the animal 
facility with free access to water and standard rodent chow. All proce-
dures involving the use of animals were performed in accordance with 
the guidelines presented by Purdue University's Animal Care and Use 
Committee. Unless otherwise indicated, 2-month-old adult mice were 
used in this study. 
2.2. Generation of MyoD-Knockout C2C12 Cell Lines 
2.2.1. Generation of Cas9-Overexpressing C2C12 Cells 
We utilized the CRISPR-Cas9 technique to mutate the MyoD gene in 
C2C12 cell line. To examine the efficiency of gRNAs, we generated a 
C2C12 cell line with Cas9 overexpressing by transfecting cells with the 
plasmid PX459 (Ran et al., 2013). PX459 contains the Cas9 protein 
with a FLAG tag and a puromycin resistant gene. Puromycin (1 μg/ml) 
selection was used to purify cells transfected with PX459, and FLAG an-
tibody was used to verify the expression of Cas9 in C2C12 cells 
(C2C12Cas9). 
2.2.2. Selection of gRNA Targets 
We used CRISPR Design (http://crispr.mit.edu/) to choose gRNA tar-
gets of MyoD (Ran et al., 2013). The gRNAs were generated by in vitro 
transcription according to the online protocol (http:// 
www.crisprflydesign.org/grnatranscription/). Then the gRNAs (1 μg 
for each gRNA/106 cells) were electroporated into C2C12Cas9 cells. For 
the control sample, we only gave C2C12Cas9 cells electric shocks. One 
day after the electroporation, we collected the cells, extracted DNA 
and amplified the region around the target sites by PCR. Clones contain-
ing cleaved bands in the gRNA treated sample but not in the control 
sample were sequenced to confirm correct targeting. 
2.2.3. MyoD KO Cell Line Selection 
We chose the gRNA target close to the 5′ of the MyoD gene and 
cloned it into the PX459 plasmid (PX459MyoD). Wildtype C2C12 cells 
were electroporated with PX459MyoD or PX459 (1 μg/106 cell). Two 
days after electroporation, puromycin (1 μg/ml) was added to the cul-
ture medium. Five days after puromycin selection, the remaining cells 
electroporated with PX459 were collected as control for the following 
studies. The remaining cells electroporated with PX459MyoD were de-
tached by 0.25% trypsin and transferred to 48-well plates by serial dilu-
tion. When the cell confluency was over 70%, cells were passaged and 
parts of them were used to do DNA extraction, PCR amplification and se-
quencing. Cells containing predicted genomic alteration were cloned a 
second time to achieve homogeneity. 
2.2.4. Off-target Detection 
The gRNA off-targets were searched by CRISPR Design. None of the 
10 most likely off-target sites by the gRNA selected in this study were lo-
cated in the gene body. The top 5 potential off-target sites (Table S1) 
were PCR amplified using genomic DNA as templates. The PCR products 
were subjected to T7EN1 cleavage assay. The potential off-target sites 
yielding typical cleavage bands were considered as candidates. Primers 
for PCR amplification of off-target sites were listed in Table S2. 
2.3. Primary Adipocyte Isolation, Culture and Differentiation 
Interscapular BAT depots from wildtype or miR-133a mutant mice 
were collected, minced and digested with isolation buffer (DMEM sup-
plemented with 1.5 mg/ml Collagenase I) for proper time at 37 °C on a 
shaker. The digestion was stopped with DMEM containing 10% FBS, fil-
tered through 100 μm filters, and cells were pelleted at 450 ×g for 5 min. 
The cells were cultured in growth media containing DMEM, 20% FBS and 
1% P/S at 37 °C with 5% CO2 for 3 days, and then fresh media was 
changed every 2 days. Upon confluence, cells were exposed to induction 
media and then differentiation media. C2C12 cells were exposed to in-
duction media for 2 days and differentiation media for 3 days. Satellite 
cell-derived myoblasts were exposed to induction media for 6 days 
and differentiation media for 6 days. Brown preadipocytes were ex-
posed to induction media for 4 days and differentiation media for 
4 days. The induction media contains DMEM, 10% FBS, 2.85 μM insulin, 
0.3 μM dexamethasone and 0.63 mM 3-isobutyl-1-methylxanthine 
(Sigma), and the differentiation media contains DMEM, 10% FBS, 
200 nM insulin and 10 nM T3. For C2C12 cells and Satellite cell-derived 
myoblasts, we also add 1 μM Rosiglitazone to the induction media and 
differentiation media. The miR-133a mirVana miRNA mimic was pur-
chased from Ambion. The Akt dominant negative plasmid, GFP-Akt-
K179M was a kind gift from Dr. Xiaoqi Liu (Chen et al., 2015). The 
PI3K inhibitor (LY294002) was purchased from Sigma and used to 
treat C2C12 myoblasts during adipogenic induction at 10 μM 
concentration. 
2.4. Oil Red O Staining 
Cells or muscle sections were rinsed with PBS and fixed with 10% 
formaldehyde for 15 min at room temperature. Cells or muscle sections 
were stained in working solution containing 6 ml of Oil Red O (ORO) 
stock solution (5 mg/ml in isopropanol) and 4 ml ddH2O for 60 min. 
After staining, slides were washed with distilled water for 10 min and 
mounted  in glycerol mounting  medium.  
2.5. Muscle Injury and Myoblasts Transplantation 
Muscle regeneration was induced by cardiotoxin (CTX; Sigma-Al-
drich) or glycerol (Macron Fine Chemicals) injection. Mice were first 
anesthetized using a ketamine-xylazine cocktail and then the TA mus-
cles were bilaterally injured with 50 μl of 10  μM CTX  or  50  μl 50% glyc-
erol. Two days after the CTX or glycerol injury, we injected 50 μl 
concentrated adenovirus (1 × 106 cells) into injured TA muscles. For 
comparable results, the left and right TA muscles were injected with 
control and MyoDKO C2C12 myoblasts, respectively. The concentrations 
of triglyceride in TA muscles were measured using the Triglyceride Col-
orimetric Assay Kit (Cayman). Glycerol is able to degenerate and induce 
adipogenesis of skeletal muscle (Pisani et al., 2010). TA muscle injection 
with glycerol was performed to induce adipogenic induction of 2– 
3 month old wild-type and MyoD−/− mice. Ten days after injection, 
muscle tissues were harvested for ORO staining and RNA isolation. 
2.6. Primary Myoblast Isolation, Culture and Differentiation 
TA muscle was harvested, and satellite cell-derived primary myo-
blasts were isolated as described previously (Motohashi et al., 2014). 
Briefly, TA muscles of MyoD−/− mice or their wild-type littermates 
were dissected and minced and then digested in type I collagenase/ 
dispase B mixture (Roche Applied Science). The digestions were filtered 
from debris for magnetic-activated cell sorting (MACS). Dissociated 
muscle cells were incubated with Anti-CD45-PE, anti-Sca-1-PE and 
anti-CD31-PE antibodies (all from eBiosciences) followed by anti-PE 
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beads (Miltenyi Biotec). LD column (Miltenyi Biotec) was used for neg-
ative selection to eliminate hematopoietic cells, endothelial cells and 
other non-muscle cells from the muscle preparation. Flow through frac-
tion was incubated with integrin α-biotin antibody (Miltenyi Biotec) 
followed by anti-biotin beads (Miltenyi Biotec). MS column (Miltenyi 
Biotec) was used for primary myoblast isolation as a positive fraction. 
Isolated primary myoblasts were cultured in growth media (F-10 
Ham's media supplemented with 17% FBS, 4 ng/ml basic fibroblast 
growth factor and 1% penicillin-streptomycin) on collagen-coated 
dishes, and the growth medium was changed every two days. Primary 
myoblasts were cultured in normal humidified tissue culture incubators 
with 5% CO2. 
2.7. Adenovirus Generation 
The adenovirus with MyoD insertion was generated using the 
AdEasy system. Briefly, the MyoD ORF was cloned using pairs of primers 
(MyoD-f and MyoD-r, Table S2), and inserted into pAdTrack-CMV plas-
mid. The formed pAdTrack-CMV-MyoD (pAdTrack-CMV as the control) 
plasmids were digested by PmeI and then transfected the DH5a compe-
tent cell with pAdEasy-1. The positive recombinant plasmid was detect-
ed by PacI digestion. Then, 293A cells (60%–70% confluent) in 10 cm 
culture dishes was transfected with the 4 μg PacI digested recombinant 
plasmid using Lipofectamine 2000 (Life Technologies) according to 
manufacturer's protocol. After 14 days incubation, the recombinant ad-
enovirus was released by four freeze–thaw–vortex cycles. Two more 
round infections were adapted to amplify the recombinant virus and 
the titers were determined by the expression of GFP. 
2.8. Immunostaining and Image Acquisition 
Myoblasts were fixed with 4% paraformaldehyde, and blocked with 
blocking buffer (5% goat serum, 2% BSA, 0.2% triton X-100, and 0.1% so-
dium azide in PBS) for at least 1 h. The samples were then incubated 
with primary antibody [MyoD (M318, RRID: AB_2148870) was from 
Santa Cruz and Perilipin (D1D8, RRID: AB_10621999) was from Cell Sig-
naling] in blocking buffer overnight. After washing with PBS, the sam-
ples were incubated with secondary antibodies and DAPI or BODIPY 
493/503 for 45 min at room temperature. Fluorescent images were cap-
tured using a Leica DM 6000B fluorescent microscope. As the adenoviral 
vectors contain GFP and thus express green signals when they are trans-
duced into cells, we calculated the number of different signals only in 
GFP+ cells. 
2.9. Total RNA Extraction, cDNA Synthesis, and Real-Time PCR 
Total RNA was extracted from cells using Trizol Reagent according to 
the manufacturer's protocols. RNA was treated with RNase-free DNase I 
to remove contaminating genomic DNA. The purity and concentration 
of total RNA were measured by Nanodrop 3000 (Thermo Fisher). Ran-
dom primers and Moloney murine leukemia virus reverse transcriptase 
were used to convert RNA into cDNA. For microRNA, multiple adenosine 
nucleotides were added to 3′ end of RNAs by E. coli DNA polymerase and 
cDNAs were synthesized with a specific RT primer (Liu et al.,  2013). 
Real-time PCR was performed using Roche Lightcycler 480 PCR System 
with SYBR Green Master Mix and gene-specific primers described previ-
ously (Sun et al., 2011; Wang et al., 2015). Ct value of 18S rRNA and U6 
snRNA was used to normalize mRNA and miRNA expression, respective-
ly. The 2−ΔΔCT method was used to analyze the relative mRNA and 
miRNA expressions. 
2.10. Protein Extraction and Western Blot Analysis 
Cultured myoblasts were washed with PBS and homogenized with 
radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 8.0), 
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS). 
Protein concentrations were determined using Pierce BCA Protein 
Assay Reagent (Pierce Biotechnology, Rockford, IL). Proteins were sepa-
rated by 10% SDS-PAGE, electrotransferred onto PVDF membrane 
(Millipore Corporation, Billerica, MA), and incubated with specific pri-
mary antibodies. Igf-1rβ (C20) and Gapdh (6C5, RRID: AB_627679) an-
tibodies were from Santa Cruz; Akt (#9272, RRID: AB_329827) and  pAkt  
(Ser473) (#9271, RRID: AB_329825) antibodies were from Cell Signal-
ing. Immunodetection was performed using enhanced chemilumines-
cence (ECL) Western blotting substrate (Pierce Biotechnology, 
Rockford, IL) and detected with FluoChem R imaging system 
(ProteinSimple, CA). 
2.11. Statistical Analysis 
The data are presented with mean and standard deviation (SD). P-
values were calculated using unpaired two-tailed Student's t-test. P-
values b 0.05 were considered to be statistically significant. 
3. Results 
3.1. Generating MyoD-Knockout C2C12 Clones 
C2C12 cells are well-established myogenic progenitors that also 
have some limited capacity to differentiate into adipocytes (Teboul et 
al., 1995). In order to investigate the role of MyoD in myogenic versus 
adipogenic fate determination, we sought to knockout (KO) MyoD in 
C2C12 cells using the CRISPR-Cas9 technique. To improve the targeting 
efficiency, we first established C2C12 cells stably overexpressing Cas9 
(C2C12Cas9), and then transfected the cells with two in vitro transcribed 
guide RNAs (gRNAs) targeting the exon 1 of MyoD (Fig. 1a). Two cleaved 
bands were only visible in C2C12Cas9 myoblasts transfected with both 
gRNAs (Fig. S1a). We sequenced the 300 bp band, and found a 336 bp 
deletion in MyoD (Fig. 1b), indicating that both gRNAs work efficiently 
with Cas9 to edit MyoD. 
To minimize genome-wide off-target mutations, we only cloned the 
sequence of Target 1 (Fig. 1a) to the plasmid PX459 to establish MyoD-
knockout clones. Of the 21 cell clones established, we found through se-
quencing that most clones had mutations in one of the two MyoD alleles, 
with two clones containing 1-bp or 11-bp frame-shifting deletions in 
both MyoD alleles (Fig. S1b). These mutations resulted in truncated 
MyoD proteins of 55 and 72 amino acid residues lacking the basic 
Helix-loop-Helix domain, respectively (Fig. S1b). We further performed 
immunohistochemistry staining on the MyoDKO cell clones using a well-
established MyoD antibody. Control C2C12 myoblasts exhibited strong 
MyoD signals, whereas both MyoD knockout cell clones lost the MyoD 
signal (Fig. 1c). The T7EN1 cleavage assays showed that no genetic mod-
ification was detected at the selected off-target sites (Fig. S1c). There-
fore, we have successfully established two clones of MyoD knockout 
C2C12 cells. We named them MyoDKO C2C12 cells to distinguish them 
from MyoD−/− primary myoblasts isolated from skeletal muscles of 
MyoD mutant mice. 
3.2. Loss of MyoD Facilitates Adipogenic Transdifferentiation of C2C12 
Myoblasts 
Consistent with previous report that MyoD–/– primary myoblasts 
have reduced differentiation potential (Cornelison et al., 2000; Dedieu 
et al., 2002; Sabourin et al., 1999), the MyoDKO C2C12 cells showed dif-
ferentiation defect when induced in myogenic differentiation medium 
(Fig. S1d). To examine the adipogenic potential of the MyoDKO C2C12 
myoblasts, we exposed confluent cultures to an adipogenic differentia-
tion medium. The control cells showed elongated morphology charac-
teristic of myotubes, whereas many MyoDKO cells differentiated into 
round, lipid droplet-containing adipocyte-like cells (Fig. 1d). Oil Red O 
(ORO) staining for neutral triglycerides revealed that control cells only 
had a few oil droplets. In contrast, MyoDKO cells exhibited large regions 
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Fig. 1. Loss of MyoD facilitates the adipogenic transdifferentiation of C2C12 myoblasts. (a) Schematic diagram of MyoD partial protein coding region and the 2 targeting loci of MyoD 
sgRNA. The targeting loci are in red. (b) DNA sequence map around the targeting locus of the cleaved band amplified from myoblasts transfected with both gRNAs. (c) 
Immunostaining of MyoD (Red) and DAPI (Cyan) in control and MyoDKO C2C12 myoblasts. (d) Representative images of ORO staining of C2C12 myoblasts after adipogenic 
differentiation. (e and f) qPCR analysis of Myog (e) and adipogenic markers genes (f). Error bars represent mean with SD of five independent biological replicates.⁎P b 0.05 (Student's 
t-test). 
of cells containing widespread oil droplets (Fig. 1d). The mutation of 
MyoD also dramatically downregulated the myogenic marker gene 
Myog (Fig. 1e), but significantly upregulated the adipogenic marker 
genes Fabp4, Fasn and Cebpα by 6-14 fold (Fig. 1f), indicating loss of 
MyoD facilitates adipogenic transdifferentiation of C2C12 cells. 
As MyoD regulates miR-133 (Rao et al., 2006), which targets Igf1r 
(Huang et al., 2011), we hypothesize that loss of MyoD upregulates 
Igf1r and consequently amplifies the downstream PI3K–Akt signaling 
to promote adipogenesis (Fig. 2a). Indeed, MyoDKO cells expressed sig-
nificantly lower levels (~90% reduction) of miR-133a and miR-133b (Fig. 
2b), accompanied by 2-fold increase in the expression of Igf1r both at 
mRNA and protein levels (Fig. 2c and d). Within two days after incuba-
tion with adipogenic induction media, MyoDKO cells had increased 
levels of the phosphorylated Akt (pAkt), but normal levels of total Akt 
a b C d 
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Fig. 2. The miR-133/Igf1r/Akt signaling pathway mediates adipogenesis of MyoDKO cells. (a) Hypothetical model showing how MyoDKO induces adipogenic transdifferentiation of C2C12 
myoblasts. (b and c) qPCR analysis of miR-133 (b) and Igf1r (c). (d) Western blot analysis of the expressions of Igf1r and pAkt in control and MyoDKO myoblasts. (e) Strategies to examine 
the role of PI3K and Akt in transdifferentiation of myoblasts to adipocytes. (f) qPCR analysis of adipogenic marker genes under different treatments. Error bars represent mean with SD of 
five independent biological replicates.⁎P b 0.05 (Student's t-test). 
(Fig. 2d). In parallel to the activation of Akt, the levels of adipogenic 
marker genes (Fabp4, Cebpα and Fasn) were 2-3 fold higher in MyoDKO 
cells than in control cells (Fig. 2e and  f).  
To examine if miR-133 reduction mediates adipogenesis of MyoDKO 
cells, we overexpressed miR-133a in cultured MyoDKO cells (Fig. S2a). 
Electroporation-mediated gene transfer resulted in up to 840-fold ele-
vation in the expression of miR-133a (Fig. S2a). As a consequence, the 
mRNA levels of Igf1r, Fabp4, Fasn and Cebpα in MyoDKO cells were nor-
malized to those in control cells (Fig. S2b). To determine if activation 
of PI3K–Akt is required for the adipogenic conversion of C2C12 myo-
blasts, the MyoDKO cells were transfected with a plasmid expressing 
the dominant negative Akt mutant (K179M), or incubated with a PI3K 
inhibitor LY294002 (Fig. 2e). Both treatments normalized the mRNA 
levels of Fabp4, Fasn and Cebpα in MyoDKO to similar levels as the con-
trol cells (Fig. 2f), indicating that PI3K–Akt activation is required for 
the upregulation of adipogenic gene expression in MyoDKO C2C12 
cells. Together, loss of MyoD facilitates adipogenic transdifferentiation 
of C2C12 cells through miR-133/Igf1r/Akt signaling pathway. 
3.3. Loss of MyoD Facilitates Brown Adipogenic Transdifferentiation of Sat-
ellite Cells 
Brown adipocytes and muscle satellite cells share a common devel-
opmental origin (Seale et al., 2008). As the loss of MyoD in C2C12 myo-
blasts facilitates adipogenic transdifferentiation, we hypothesize that 
loss of MyoD may convert satellite cells to brown adipocytes. To test 
this hypothesis, we examined cultured primary myoblasts derived 
from skeletal muscle satellite cells of MyoD−/− mice. Under growth 
conditions, MyoD−/− myoblasts expressed slightly increased levels of 
Myf5 and strikingly reduced levels of Myog and miR-133 (Fig. 3a). Con-
sistence with the reports that miR-133 targets Prdm16 (Liu et al., 2013; 
Trajkovski et al., 2012; Yin et al., 2013), this reduced levels of miR-133 is 
associated with increased expression of Prdm16 in MyoD−/− myoblasts 
(Fig. 3a). Interestingly, the expression of Pparγ2, a key transcriptional 
factor for adipogenesis (Tontonoz et al., 1994), was decreased in 
MyoD−/− myoblasts (Fig. 3a). However, the expression of several 
adipogenic marker miRNAs did not change their expression in 
MyoD−/− myoblasts (Fig. 3a). These results support that MyoD KO 
does not spontaneously promote adipogenesis in the absence of 
adipogenic induction (Asakura et al., 2001). 
We next examined if MyoD−/− myoblasts can transdifferentiate into 
brown adipocytes under adipogenic differentiation medium containing 
1 μM Rosiglitazone, a Pparγ activator (Fig. 3b). Strikingly, MyoD−/− 
myoblasts robustly differentiated into lipid-filling adipocytes as indicat-
ed by ORO staining (Fig. 3c). In contrast, wild-type (WT) myoblasts did 
not transdifferentiate into adipocytes under identical culture conditions 
(Fig. 3c). After differentiation, brown adipogenic markers genes Prdm16, 
Ucp1 and Lhx8 were expressed 16-fold, 30-fold and 100-fold higher in 
MyoD−/− cells than in WT cells (Fig. 3d). The adipogenic master regula-
tor Pparγ2 was expressed 30-fold higher in MyoD−/− cells as well (Fig. 
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Fig. 3. Loss of MyoD dramatically downregulates miR-133a, promotes brown adipocyte biogenesis and stimulates transdifferentiation of myoblasts into brown adipocytes. MyoDiCre/+ 
mice were intercrossed to generate MyoDiCre/iCre (MyoD−/−) knockout mice and WT littermates. The miRNA miR-133a; Prdm16 targets miR-193b and miR-365; adipogenic marker 
miR-143 and brown adipogenic marker miR-455 were analyzed by qPCR. (a) qPCR analysis of WT and MyoD−/− myoblasts for myogenic markers Myf5 and Myogenin, adipogenic 
markers Pparγ2 and Prdm16, and the miRNAs. (b) WT and MyoD−/− myoblasts were subjected to adipogenic induction and differentiation as shown in the schematics. (c) 
Representative images of ORO staining of adipocytes. (d and e) qPCR analysis of adipogenic markers (d) and miRNAs (e). Passage 3 primary myoblasts (purity N95%) from MyoD−/− 
and WT mice were used. Error bars represent mean with SD of 3–5 independent biological replicates.⁎P b 0.05, ⁎⁎P b 0.01 (Student's t-test). 
3d). The level of miR-133a remained low in MyoD−/− cells after 
adipogenic differentiation (Fig. 3e). However, the Prdm16 target miR-
193b was upregulated by 7-fold, and adipogenic miR-143 and miR-
455 were 17-fold and 8-fold higher, respectively, in the MyoD−/− cells 
compared with the WT cells (Fig. 3e). We conclude from these results 
that the loss of MyoD downregulates miR-133a, upregulates Prdm16, 
and promotes the transdifferentiation of myoblasts into brown adipo-
cytes under adipogenic conditions. 
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3.4. Loss of MyoD Facilitates Adipogenic Transdifferentiation of Myoblasts 
in vivo 
To investigate the adipogenic potential of MyoDKO C2C12 myoblasts 
in vivo, control and MyoDKO C2C12 cells were injected into injured TA 
muscles of mdx mice, which lack the expression of dystrophin, a muscle 
membrane protein. Eight days after cell transplantation, TA muscles 
injected with MyoDKO C2C12 cells formed fewer dystrophin+ myofibers 
compared with muscles injected with control C2C12 cells (Fig. S3a and 
b). Interestingly, the reduced myogenic capacity of MyoDKO cells is ac-
companied by a concomitant increase in formation of BODIPY-label ad-
ipocytes (Fig. S3a). Consistently, the concentration of triglycerides (TG) 
was 40% higher (1.5 for WT C2C12 cells and 2.1 for MyoDKO C2C12 cells) 
in muscles grafted with MyoDKO C2C12 cells compared with those 
injected with WT C2C12 cells (Fig. S3c). To directly trace the fate con-
version of injected C2C12 cells, we used adenovirus to overexpress 
GFP in control and MyoDKO C2C12 cells prior to grafting into glycerol-
injected TA muscles (Fig. 4a). Eight days after cell graft, the muscles 
injected with MyoDKO C2C12 cells had about 3-fold more GFP+ 
BODIPY+ cells compared with muscles injected with control C2C12 
cells (Fig. 4a and b). Consistently, the expression levels of adipogenic 
marker genes Fabp4 and Cebpα were higher in muscles injected with 
MyoDKO C2C12 cells than in those injected with control C2C12 cells 
(Fig. 4c). These results indicate that loss of MyoD facilitates adipogenic 
transdifferentiation of C2C12 myoblasts in vivo. 
To further investigate the adipogenic transdifferentiation of 
MyoD−/− satellite cells in vivo, TA muscles of MyoD−/− mice and WT 
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Fig. 4. Loss of MyoD facilitates adipogenic transdifferentiation of myoblasts in vivo. (a) Immunostaining of BODIPY (red) in TA muscles injected with control or MyoDKO C2C12 cells. Arrows 
indicate GFP+BODIPY+ cells. (b) The ratio of BODIPY signal in GFP+ cells in TA muscles injected with control or MyoDKO C2C12 cells. (c) qPCR analysis of adipogenic marker genes. (d) 
Representative images of ORO staining of regenerated TA muscles of WT and MyoD−/− mice. The MyoD−/− mice (Rudnicki et al., 1992) were generously provided by Dr. Michael Rudnicki. 
(e) Relative ORO intensity on WT and MyoD−/− TA muscle sections. (f) qPCR analysis of adipogenic marker genes. (g) ORO staining and anti-Perilipin staining in myoblasts isolated from 
glycerol-injured TA muscles of WT and MyoD−/− mice. Arrows indicate ORO+ or Perilipin+ cells. (h) The ratio of ORO+ and Perilipin+ cells in myoblasts isolated from injured WT and 
MyoD−/− TA muscles. Four sections were analyzed for each sample. Error bars represent mean with SD of three independent biological replicates.⁎P b 0.05 (Student's t-test). 
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and adipogenesis. On day 10 after glycerol injection, TA muscle sections 
were stained with ORO to label lipids (Fig. 4d). Strikingly, TA muscles of 
MyoD−/− mice had much more pronounced ORO labeling (Fig. 4d), 
with a 7-fold increase in the density of ORO signal compared to WT 
mice (Fig. 4e). Consistently, mRNA levels of adipogenic marker genes 
Fasn and Pparγ2 were higher in TA muscles of MyoD−/− mice compared 
with those in WT mice (Fig. 4f). However, mRNA levels of brown 
adipogenic marker gene Ucp1 were comparable in TA muscles of WT 
and MyoD−/− mice (Fig. 4f). To confirm the satellite cell origin of the 
ORO+ cells in glycerol treated MyoD−/− muscles, primary myoblasts 
were isolated from TA muscles using magnetic-activated cell sorting 
(MACS) at 4 days after glycerol injection, prior to adipogenic differenti-
ation (Fig. 4g). Strikingly, the percentage of ORO+ and Perilipin+ myo-
blasts was 4-fold and 28-fold higher, respectively, in myoblasts isolated 
from MyoD−/− mice than in the myoblasts isolated from WT mice (Fig. 
4h). We conclude that loss of MyoD facilitates adipogenic 
transdifferentiation of satellite cell-derived myoblasts in vivo. 
3.5. Overexpression of MyoD in BAT Preadipocytes Inhibits Adipogenesis 
To further examine the role of MyoD in brown adipocyte versus 
myoblast fate switch, we used adenoviruses to overexpress MyoD-GFP 
(MyoDOE) or  GFP only (control) in BAT SVF preadipocytes isolated 
from WT mice. Two days after transduction of adenoviral vectors, 
brown preadipocytes were induced to undergo adipogenesis. ORO 
staining showed MyoD but not GFP markedly decreased lipid accumula-
tion in brown adipocytes differentiated from BAT SVF cells (Fig. 5a). We 
also utilized BODIPY to label brown adipocytes (Fig. 5b and c). Whereas 
82% (387 out of 473) of GFP+ cells were BODIPY+ in the control group, 
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Fig. 5. Overexpression of MyoD impairs brown adipogenesis of wildtype BAT SVF cells. (a) ORO staining of brown adipocytes differentiated from wildtype BAT SVF cells transduced with 
control or MyoDOE adenovirus. (b and c) Immunostaining of BODIPY (red) in control (b) and MyoDOE (c) brown adipocytes (d) The ratio of BODIPY signal in GFP+ cells in control and 
MyoDOE brown adipocytes. Five different areas analyzed in each experiment. (e–g) qPCR analysis of myogenic markers (e) miRNAs (f) and adipogenic markers (g). Error bars 
represent mean with SD of three independent biological replicates.⁎P b 0.05 (Student's t-test). 
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BODIPY+ in the MyoDOE group (Fig. 5d), representing a 6-fold decrease. 
We noticed in the MyoDOE group a negative correlation between GFP 
and BODIPY signals: there was essentially no BODIPY signal in regions 
with high densities of GFP signals (Fig. S4a). In addition, a group of 
MyoDOE brown preadipocytes showed elongated myotube-like mor-
phologies (Fig. S4a), and about 70% (115 out of 165) of the elongated 
MyoDOE cells expressed myosin heavy chain (MF20+) (Fig. S4b and c), 
indicating that MyoD transdifferentiates brown preadipocytes into 
myocyte. At the molecular level, MyoD overexpression was correlated 
with 18-fold and 288-fold elevation in the expression of Myog and 
eMHC, respectively (Fig. 5e). In parallel, the expression levels of miR-
133a and miR-133b were upregulated by 28-fold and 30-fold, respec-
tively (Fig. 5f). By contrast, brown adipogenic marker genes Prdm16 
and Ucp1 were decreased by 92% and 70%, respectively, and other 
adipogenic marker genes Fabp4, Adipoq and Cebpα were also 
downregulated by 82%, 81% and 69%, respectively (Fig. 5g). Together, 
our data indicate that BAT adipogenesis is inhibited by ectopic expres-
sion of MyoD. 
3.6. Deletion of miR-133a Blunts the Inhibitory Effect of MyoD on Brown 
Adipogenesis 
To investigate whether miR-133 mediates the inhibitory effect of 
MyoD on adipogenesis, we used adenoviral vectors to overexpress 
MyoD in miR-133a1/a2 double knockout (miR-133a−/−) BAT SVF 
cells. MyoD overexpression decreased lipid accumulation in miR-
133a−/− brown adipocytes differentiated from BAT SVF cells (Fig. 6a), 
but to a much lesser extent compared with the level of decrease in 
WT brown adipocytes (Fig. 5a). By labeling brown adipocytes with 
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Fig. 6. Loss of miR-133a alleviates the inhibitory effect of MyoD on brown adipogenesis. (a) ORO staining of brown adipocytes differentiated from miR-133a−/− BAT SVF cells transduced 
with control or MyoDOE adenovirus. (b and c) Immunostaining of BODIPY (red) in control (b) and MyoDOE (c) miR-133a−/− brown adipocytes. (d) Ratios of BODIPY signal in GFP+ cells in 
control and MyoDOE miR-133a−/− brown adipocytes. Five different areas analyzed in each experiment. (e) Fold changes of GFP+BODIPY+ cells inWT and miR-133a−/− brown adipocytes 
after MyoD overexpression (f) qPCR analysis of miR-133a and miR-133b. (g and h) Fold changes of myogenic markers (g) and adipogenic markers (h) in WT and miR-133a−/− brown 
adipocytes after MyoD overexpression. Error bars represent mean with SD of three independent biological replicates.⁎P b 0.05 (Student's t-test). 
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cells were BODIPY+ in the control group, and 48% (229 out of 476) of 
the GFP+ cells were BODIPY+ in the MyoDOE group (Fig. 6d), 
representing b2-fold decrease (Fig. 6e). By contrast, MyoD decreased 
the ratio of GFP+/BODIPY+ cells by over 6-fold in WT brown adipocytes 
(Fig. 6e). MyoD overexpression similarly increased the levels of miR-
133b by 30-fold in both WT and miR-133a−/− brown adipocytes (Figs. 
6f and 5f). In addition, MyoD overexpression increased the levels of 
Myog and eMHC to similar extent in WT and miR-133a−/− brown adipo-
cytes (Fig. 6g), suggesting that MyoD induces myogenesis independent 
of miR-133a. However, the extent of MyoD-induced suppression of 
adipogenic markers was much lesser in the miR-133a−/− compared to 
WT brown adipocytes (Fig. 6h). Specifically, the MyoD overexpression 
induced fold decreases of Fabp4, Adipoq, Cebpα, Ucp1 and Prdm16 
were 5-fold, 5-fold, 3-fold, 14-fold and 3-fold, respectively, in WT 
brown adipocytes (Fig.6h). In contrast, in the absence of miR-133a, 
MyoD only decreased the expression of these genes by 1.6-fold, 2-fold, 
1.5-fold, 3-fold and 1.5-fold, respectively (Fig. 6h). These results demon-
strate that MyoD inhibits brown adipogenesis partly through miR-133a. 
4. Discussion 
We identified MyoD as a negative regulator of brown adipocyte de-
velopment. This result extends the function of MyoD in addition to its 
well-established role as a positive regulator of myogenesis. With the 
CRISPR-Cas9 technique, we successfully established 2 clones of MyoDKO 
myoblasts and discovered that loss of MyoD facilitates the adipogenic 
transdifferentiation of C2C12 myoblasts. Consistent with our study is 
that downregulation of MyoD mRNA by RNaseL in C2C12 myogenic 
cells led to adipogenic differentiation (Salehzada et al., 2009). We 
show that the MyoD/miR-133/Igf1r/PI3K/Akt signaling pathway is in-
volved in the promotion of adipogenesis in MyoDKO cells. Insulin, a com-
ponent of the adipogenic differentiation medium, binds to Igf1r to 
activate the p85 regulatory subunit of PI3K, which subsequently phos-
phorylates and activates Akt (Belfiore et al., 2009). Akt then inhibits tu-
berous sclerosis complex 2 and activate the mammalian target of 
rapamycin complex 1 to promote insulin-induced adipogenesis 
(Zhang et al., 2009). 
Loss of MyoD is necessary but not sufficient to promote brown adi-
pogenesis of myoblasts. MyoD−/− myoblasts expressed dramatically 
lower levels of miR-133a, which led to the upregulation of Prdm16, 
without increasing expression of Pparγ2, a master regulator of adipo-
genesis. Although Prdm16 primes brown adipogenesis (Seale et al., 
2008), the adipogenic conversion of myoblasts requires activation of 
Pparγ (Yeow et al., 2001). For example, the addition of rosiglitazone 
in adipogenic medium was required to activate Pparγ to execute the 
conversion. This also explains why MyoD−/− myoblasts did not result 
in conversion of myoblasts to brown adipocytes spontaneously in the 
absence of adipogenic induction. Interestingly, although MyoD−/− sat-
ellite cells can transdifferentiate into adipocytes under adipogenic con-
ditions in vivo, these adipocytes are UCP1− . This observation suggests 
that additional factors, such as Notch signaling and sympathetic inner-
vation (Bartness et al., 2010; Pasut et al., 2016), may be required to in-
duce UCP1 expression in the transdifferentiated MyoD−/− adipocytes. 
A previous study reported that MyoD mutant mice have normal 
interscapular BAT mass (Borensztein et al., 2012). This may be due to 
the relative late activation of MyoD after Pax7/Myf5 during myogenesis 
and brown adipogenesis (Rudnicki et al., 1993; Sanchez-Gurmaches 
and Guertin, 2014). Therefore, deletion of MyoD should not affect 
brown adipogenesis, which takes place before MyoD activation in the 
Pax7/Myf5 progenitors. 
Several myogenic factors including MyoD are expressed in brown 
preadipocytes, with expression diminishing during differentiation 
(Timmons et al., 2007), indicating that inhibition of MyoD is required 
for brown adipogenesis. We demonstrate that overexpression of 
MyoD dramatically upregulates miR-133 expression in brown adipo-
cytes. This is consistent with the report that MyoD binds to regions 
upstream of miR-133(Rao et al., 2006). As miR-133 represses Prdm16 
(Liu et al., 2013; Trajkovski et al., 2012; Yin et al., 2013), the MyoD/ 
miR-133/Prdm16 signaling cascade explains the inhibitory effect of 
MyoD on brown adipogenesis. Forced expression of MyoD in adipocyte 
precursors or white adipocytes similarly inhibits adipogenic differentia-
tion, indicating MyoD inhibits adipogenesis in general regardless of 
Prdm16 (Kocaefe et al., 2005; Weintraub et al., 1989). This is probably 
achieved through the transdifferentiation of brown preadipocytes into 
MF20+ myocytes and miR-133 mediated inhibition of Igf1r which is re-
quired for adipogenesis (Boucher et al., 2010). 
We show that miR-133 is an important mediator of MyoD-induced 
inhibition of adipogenesis. There are two mature miR-133 isomers: 
miR-133a and miR-133b that only differ in one nucleotide. The miR-
133a is encoded by two genes (miR-133a1 and miR-133a2), and double 
mutant mice exhibit cardiac and skeletal muscle myopathy, along with 
browning of subcutaneous white adipose tissue (Liu et al., 2011; Liu et 
al., 2008; Liu et al., 2013). By contrast, the miR-133b mutant mice are 
normal (Boettger et al., 2014), indicating that miR-133a has more im-
portant physiological functions than miR-133b. The observation that 
deletion of miR-133a only partially blocked the inhibitory function of 
MyoD on brown adipogenesis suggests that additional factors are in-
volved in mediating MyoD function in brown adipocytes. It is possible 
that the residual miR-133b partially compensated for the miR-133a 
loss-of-function. Our finding that ectopic expression of MyoD inhibits 
brown adipogenesis and promotes myogenic transdifferentiation sug-
gests that inhibition of myogenesis is necessary for brown adipogenic 
commitment of Pax7/Myf5 progenitors. As MyoD KO alone is insuffi-
cient to block embryonic myogenesis, the brown adipocyte develop-
ment is not affected. Supporting this notion, complete blockage of 
myogenesis in MyoD/Myf5 and MyoD/Igf2 double knockout mice both 
exhibit more pronounced adipogenesis (Borensztein et al., 2012; 
Kablar et al., 2003). MyoD inhibits adipogenesis and the expression of 
Prdm16, and Prdm16 reciprocally inhibits myogenesis and the expres-
sion of MyoD (Seale et al., 2008). The mutual exclusion of the two mas-
ter regulators balances and determines the developmental separation of 
BAT and muscle progenitors during embryogenesis. 
In summary, our results establish MyoD as a negative regulator of 
brown adipocyte development through upregulating miR-133 to sup-
press Igf1r and Prdm16 (Fig. 7). Our work suggests that inhibition of 
MyoD in patient-derived myoblasts may promote their 









Fig. 7. Diagram summarizing the role of MyoD in brown adipocyte and myoblast fate 
determination. Loss of MyoD stimulates transdifferentiation of myoblasts into brown 
adipocytes. Conversely, overexpression of MyoD inhibits brown adipogenesis through 
myogenic transdifferentiation of brown adipocytes and miR-133-mediated mRNA decay 
of Prdm16 and Igf1r. 
222 C. Wang et al. / EBioMedicine 16 (2017) 212–223 
Acknowledgements and Funding Sources 
This work was supported by a grant from the US National Institutes 
of Health (R01AR060652 to S.K.) and Purdue incentive grant from 
Purdue University Office of Vice President for Research (OVPR, Cat1, 
206732) to S.K. We thank Dr. Xiaoqi Liu (Biochemistry, Purdue Univer-
sity) for generously providing pAkt (K179M). Dr. Eric Olson (UT South-
western Medical Center) for generously providing miR-133a1/a2 
double knockout mice. Dr. Michael Rudnicki (Ottawa Health Research 
Institute) for generously providing MyoD−/− mice. Jun Wu for mouse 
colony maintenance and members of the Kuang laboratory for valuable 
comments. 
Conflict of Interest Statement 
The authors declare no actual or potential competing financial 
interests. 
Author Contributions 
C.W. and S.K. conceived the project, designed the experiments and 
prepared the manuscript. C.W., W.L., Y.N., M.Q., A.A., H.H. and F.Y. per-
formed the experiments. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at http://dx. 
doi.org/10.1016/j.ebiom.2017.01.015. 
References 
Asakura, A., Komaki, M., Rudnicki, M., 2001. Muscle satellite cells are multipotential stem 
cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentia-
tion 68, 245–253. 
Bartness, T.J., Vaughan, C.H., Song, C.K., 2010. Sympathetic and sensory innervation of 
brown adipose tissue. Int. J. Obes. (Lond) (34 Suppl. 1), S36–S42. 
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., Vigneri, R., 2009. Insulin receptor isoforms 
and insulin receptor/insulin-like growth factor receptor hybrids in physiology and 
disease. Endocr. Rev. 30, 586–623. 
Boettger, T., Wust, S., Nolte, H., Braun, T., 2014. The miR-206/133b cluster is dispensable 
for development, survival and regeneration of skeletal muscle. Skelet. Muscle 4, 23. 
Borensztein, M., Viengchareun, S., Montarras, D., Journot, L., Binart, N., Lombes, M., 
Dandolo, L., 2012. Double Myod and Igf2 inactivation promotes brown adipose tissue 
development by increasing Prdm16 expression. FASEB J. 26, 4584–4591. 
Boucher, J., Tseng, Y.H., Kahn, C.R., 2010. Insulin and insulin-like growth factor-1 receptors 
act as ligand-specific amplitude modulators of a common pathway regulating gene 
transcription. J. Biol. Chem. 285, 17235–17245. 
Cannon, B., Nedergaard, J., 2004. Brown adipose tissue: function and physiological signif-
icance. Physiol. Rev. 84, 277–359. 
Chen, L., Li, Z., Ahmad, N., Liu, X., 2015. Plk1 phosphorylation of IRS2 prevents premature 
mitotic exit via AKT inactivation. Biochemistry 54, 2473–2480. 
Cornelison, D.D., Olwin, B.B., Rudnicki, M.A., Wold, B.J., 2000. MyoD(−/−) satellite cells in 
single-fiber culture are differentiation defective and MRF4 deficient. Dev. Biol. 224, 
122–137. 
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B., Kuo, F.C., Palmer, 
E.L., Tseng, Y.H., Doria, A., et al., 2009. Identification and importance of brown adipose 
tissue in adult humans. N. Engl. J. Med. 360, 1509–1517. 
Dedieu, S., Mazeres, G., Cottin, P., Brustis, J.J., 2002. Involvement of myogenic regulator 
factors during fusion in the cell line c2c12. Int. J. Dev. Biol. 46, 235–241. 
Hossain, P., Kawar, B., El Nahas, M., 2007. Obesity and diabetes in the developing world—a 
growing challenge. N. Engl. J. Med. 356, 213–215. 
Huang, M.B., Xu, H., Xie, S.J., Zhou, H., Qu, L.H., 2011. Insulin-like growth factor-1 receptor 
is regulated by microRNA-133 during skeletal myogenesis. PLoS One 6, e29173. 
Kablar, B., Krastel, K., Tajbakhsh, S., Rudnicki, M.A., 2003. Myf5 and MyoD activation de-
fine independent myogenic compartments during embryonic development. Dev. 
Biol. 258, 307–318. 
Kocaefe, Y.C., Israeli, D., Ozguc, M., Danos, O., Garcia, L., 2005. Myogenic program induc-
tion in mature fat tissue (with MyoD expression). Exp. Cell Res. 308, 300–308. 
Kopecky, J., Clarke, G., Enerback, S., Spiegelman, B., Kozak, L.P., 1995. Expression of the mi-
tochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic 
obesity. J. Clin. Invest. 96, 2914–2923. 
Liu, N., Bezprozvannaya, S., Williams, A.H., Qi, X., Richardson, J.A., Bassel-Duby, R., Olson, 
E.N., 2008. microRNA-133a regulates cardiomyocyte proliferation and suppresses 
smooth muscle gene expression in the heart. Genes Dev. 22, 3242–3254. 
Liu, N., Bezprozvannaya, S., Shelton, J.M., Frisard, M.I., Hulver, M.W., McMillan, R.P., Wu, Y., 
Voelker, K.A., Grange, R.W., Richardson, J.A., et al., 2011. Mice lacking microRNA 133a 
develop dynamin 2-dependent centronuclear myopathy. J. Clin. Invest. 121, 
3258–3268. 
Liu, W., Bi, P., Shan, T., Yang, X., Yin, H., Wang, Y.X., Liu, N., Rudnicki, M.A., Kuang, S., 2013. 
miR-133a regulates adipocyte browning in vivo. PLoS Genet. 9, e1003626. 
Motohashi, N., Asakura, Y., Asakura, A., 2014. Isolation, culture, and transplantation of 
muscle satellite cells. J. Vis. Exp. 
Nedergaard, J., Bengtsson, T., Cannon, B., 2007. Unexpected evidence for active brown ad-
ipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293, E444–E452. 
Ohno, H., Shinoda, K., Ohyama, K., Sharp, L.Z., Kajimura, S., 2013. EHMT1 controls brown 
adipose cell fate and thermogenesis through the PRDM16 complex. Nature 504, 
163–167. 
Olson, E.N., Klein, W.H., 1994. Bhlh factors in muscle development — dead lines and com-
mitments, what to leave in and what to leave out. Genes Dev. 8, 1–8. 
Orava, J., Nuutila, P., Lidell, M.E., Oikonen, V., Noponen, T., Viljanen, T., Scheinin, M., 
Taittonen, M., Niemi, T., Enerback, S., et al., 2011. Different metabolic responses of 
human brown adipose tissue to activation by cold and insulin. Cell Metab. 14, 
272–279. 
Ott, M.O., Bober, E., Lyons, G., Arnold, H., Buckingham, M., 1991. Early expression of the 
myogenic regulatory gene, myf-5, in precursor cells of skeletal muscle in the mouse 
embryo. Development 111, 1097–1107. 
Ouellet, V., Labbe, S.M., Blondin, D.P., Phoenix, S., Guerin, B., Haman, F., Turcotte, E.E., 
Richard, D., Carpentier, A.C., 2012. Brown adipose tissue oxidative metabolism con-
tributes to energy expenditure during acute cold exposure in humans. J. Clin. Invest. 
122, 545–552. 
Pasut, A., Chang, N.C., Rodriguez, U.G., Faulkes, S., Yin, H., Lacaria, M., Ming, H., Rudnicki, 
M.A., 2016. Notch signaling rescues loss of satellite cells lacking Pax7 and promotes 
brown adipogenic differentiation. Cell Rep. 16, 333–343. 
Pfannenberg, C., Werner, M.K., Ripkens, S., Stef, I., Deckert, A., Schmadl, M., Reimold, M., 
Haring, H.U., Claussen, C.D., Stefan, N., 2010. Impact of age on the relationships of 
brown adipose tissue with sex and adiposity in humans. Diabetes 59, 1789–1793. 
Pisani, D.F., Bottema, C.D., Butori, C., Dani, C., Dechesne, C.A., 2010. Mouse model of skel-
etal muscle adiposity: a glycerol treatment approach. Biochem. Biophys. Res. 
Commun. 396, 767–773. 
Pownall, M.E., Gustafsson, M.K., Emerson, C.P., 2002. Myogenic regulatory factors and the 
specification of muscle progenitors in vertebrate embryos. Annu. Rev. Cell Dev. Biol. 
18, 747–783. 
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., 2013. Genome engineer-
ing using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308. 
Rao, P.K., Kumar, R.M., Farkhondeh, M., Baskerville, S., Lodish, H.F., 2006. Myogenic factors 
that regulate expression of muscle-specific microRNAs. Proc. Natl. Acad. Sci. U. S. A. 
103, 8721–8726. 
Rawls, A., Valdez, M.R., Zhang, W., Richardson, J., Klein, W.H., Olson, E.N., 1998. Overlap-
ping functions of the myogenic bhlh genes mrf4 and myod revealed in double mutant 
mice. Development 125, 2349–2358. 
Rudnicki, M.A., Braun, T., Hinuma, S., Jaenisch, R., 1992. Inactivation of MyoD in mice leads 
to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal 
muscle development. Cell 71, 383–390. 
Rudnicki, M.A., Schnegelsberg, P.N.J., Stead, R.H., Braun, T., Arnold, H.H., Jaenisch, R., 1993. 
Myod or myf-5 is required for the formation of skeletal-muscle. Cell 75, 1351–1359. 
Sabourin, L.A., Girgis-Gabardo, A., Seale, P., Asakura, A., Rudnicki, M.A., 1999. Reduced dif-
ferentiation potential of primary MyoD−/− myogenic cells derived from adult skel-
etal muscle. J. Cell Biol. 144, 631–643. 
Salehzada, T., Cambier, L., Vu Thi, N., Manchon, L., Regnier, L., Bisbal, C., 2009. 
Endoribonuclease L (RNase L) regulates the myogenic and adipogenic potential of 
myogenic cells. PLoS One 4, e7563. 
Sanchez-Gurmaches, J., Guertin, D.A., 2014. Adipocytes arise from multiple lineages that 
are heterogeneously and dynamically distributed. Nat. Commun. 5, 4099. 
Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scime, A., Devarakonda, S., 
Conroe, H.M., Erdjument-Bromage, H., et al., 2008. PRDM16 controls a brown fat/skel-
etal muscle switch. Nature 454, 961–967. 
Sun, L., Xie, H., Mori, M.A., Alexander, R., Yuan, B., Hattangadi, S.M., Liu, Q., Kahn, C.R., 
Lodish, H.F., 2011. Mir193b-365 is essential for brown fat differentiation. Nat. Cell 
Biol. 13, 958–965. 
Teboul, L., Gaillard, D., Staccini, L., Inadera, H., Amri, E.Z., Grimaldi, P.A., 1995. 
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. 
J. Biol. Chem. 270, 28,183–28,187. 
Timmons, J.A., Wennmalm, K., Larsson, O., Walden, T.B., Lassmann, T., Petrovic, N., 
Hamilton, D.L., Gimeno, R.E., Wahlestedt, C., Baar, K., et al., 2007. Myogenic gene ex-
pression signature establishes that brown and white adipocytes originate from dis-
tinct cell lineages. Proc. Natl. Acad. Sci. U. S. A. 104, 4401–4406. 
Tontonoz, P., Hu, E., Spiegelman, B.M., 1994. Stimulation of adipogenesis in fibroblasts by 
PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147–1156. 
Trajkovski, M., Ahmed, K., Esau, C.C., Stoffel, M., 2012. MyomiR-133 regulates brown fat 
differentiation through Prdm16. Nat. Cell Biol. 14, 1330–1335. 
van der Lans, A.A., Hoeks, J., Brans, B., Vijgen, G.H., Visser, M.G., Vosselman, M.J., Hansen, J., 
Jorgensen, J.A., Wu, J., Mottaghy, F.M., et al., 2013. Cold acclimation recruits human 
brown fat and increases nonshivering thermogenesis. J. Clin. Invest. 123, 3395–3403. 
van Marken Lichtenbelt, W.D., Vanhommerig, J.W., Smulders, N.M., Drossaerts, J.M., 
Kemerink, G.J., Bouvy, N.D., Schrauwen, P., Teule, G.J., 2009. Cold-activated brown ad-
ipose tissue in healthy men. N. Engl. J. Med. 360, 1500–1508. 
Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M., 
Laine, J., Savisto, N.J., Enerback, S., et al., 2009. Functional brown adipose tissue in 
healthy adults. N. Engl. J. Med. 360, 1518–1525. 
Wang, C., Liu, W., Liu, Z., Chen, L., Liu, X., Kuang, S., 2015. Hypoxia inhibits myogenic dif-
ferentiation through p53 protein-dependent induction of bhlhe40 protein. J. Biol. 
Chem. 290, 29,707–29,716. 
223 C. Wang et al. / EBioMedicine 16 (2017) 212–223 
Weintraub, H., Tapscott, S.J., Davis, R.L., Thayer, M.J., Adam, M.A., Lassar, A.B., Miller, A.D., Yoneshiro, T., Aita, S., Matsushita, M., Kayahara, T., Kameya, T., Kawai, Y., Iwanaga, T., 
1989. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast Saito, M., 2013. Recruited brown adipose tissue as an antiobesity agent in humans. 
cell lines by forced expression of MyoD. Proc. Natl. Acad. Sci. U. S. A. 86, 5434–5438. J. Clin. Invest. 123, 3404–3408. 
Yeow, K., Phillips, B., Dani, C., Cabane, C., Amri, E.Z., Derijard, B., 2001. Inhibition of Zhang, H.H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R.M., Wu, C.L., Manning, B.D., 
myogenesis enables adipogenic trans-differentiation in the C2C12 myogenic cell 2009. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS 
line. FEBS Lett. 506, 157–162. One 4, e6189. 
Yin, H., Pasut, A., Soleimani, V.D., Bentzinger, C.F., Antoun, G., Thorn, S., Seale, P., Fernando, 
P., van Ijcken, W., Grosveld, F., et al., 2013. MicroRNA-133 controls brown adipose de-
termination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab. 17, 
210–224. 
